This article is more than 5 years old. Information may no longer be current.

FDA grants marketing permission for diabetic foot ulcer treatment device

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has permitted the marketing for the first shock-wave device for the use of treating diabetic foot ulcers, according to an agency press release.

The device, Dermapace System from Sanuwave Inc., is intended for treatment of chronic, full-thickness diabetic foot ulcers with wound areas no larger than 16 cm² extending through the epidermis, dermis, tendon or capsule, without bone exposure. The device is an external system that employs pulses of energy to stimulate the wound and is intended for use in adults aged at least 22 years with diabetic foot ulcers of more than 30 days’ duration. The device should be used along with standard care.

Permission for marketing comes after review of two multicenter, randomized, double-blind studies with 336 patients with diabetes assigned to usual care (wet to dry dressings or removal of the damaged tissues) plus the Dermapace System or usual care and non-working shock-wave therapy. A 44% wound closure rate was observed in the group assigned to the Dermapace System compared with 30% wound closure in the non-working shock-wave therapy group.

“Diabetes is the leading cause of lower limb amputations,” Binita Ashar, MD, director of the division of surgical devices in the FDA’s center for devices and radiological health, said in the release. “The FDA is dedicated to making technologies available that can help improve the quality of life for those with chronic diseases. Additional options for successfully treating and healing ulcer wounds may help prevent lower limb amputations.”